Publications by authors named "Susan Shoaf"

Claim this Profile
T
Tolvaptan pharmacokinetics and pharmacodynamics in adolescents with autosomal dominant polycystic kidney disease.
Susan E Shoaf, Kimberly Sikes

Eur J Pediatr· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Thorough QT Trial Using Concentration-QT Analysis to Evaluate the Effects of Centanafadine on Cardiac Repolarization.
Osman S Turkoglu, Xiaofeng Wang, Jennifer Repella-Gordon, Susan E Shoaf

Clin Pharmacol Drug Dev· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conducting clinical trials with self-collection of pharmacokinetic samples: Experience from an exploratory, phase 1, open-label trial of centanafadine SR in healthy individuals.
Chelsea Ye, Tatiana Shablinski, Susan E Shoaf, Chris Chung, Michelle Bullock

Contemp Clin Trials Commun· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
At-Home Self-Collection of Pharmacokinetic Data: Design and Results From a Phase 1 Open-Label Feasibility Trial.
Arash Raoufinia, Susan E Shoaf, Brian Rothman, Chelsea Ye, Chris Chung

Clin Pharmacol Drug Dev· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing Effects of Tolvaptan and Instruction to Increase Water Consumption in ADPKD: Post Hoc Analysis of TEMPO 3:4.
Joga Gobburu, Vijay Ivaturi, Xiaofeng Wang, Susan E Shoaf, Pravin Jadhav

Kidney360· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults.
David Matuskey, Jean-Dominique Gallezot, Nabeel Nabulsi, Shannan Henry, Kristen Torres, Susan E Shoaf

J Psychopharmacol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.
Djalila Mekahli, Lisa M Guay-Woodford, Melissa A Cadnapaphornchai, Larry A Greenbaum, Mieczyslaw Litwin, Susan E Shoaf

Clin J Am Soc Nephrol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.
Susan E Shoaf, Patricia Bricmont, Jennifer Repella Gordon

Clin Transl Sci· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD.
Ronald D Perrone, Arlene B Chapman, Dorothee Oberdhan, Frank S Czerwiec, Olga Sergeyeva, Susan E Shoaf

Kidney Int Rep· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations.
Ronald D Perrone, Arlene B Chapman, Dorothee Oberdhan, Frank S Czerwiec, Olga Sergeyeva, Susan E Shoaf

Kidney Int Rep· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials.
Susan E Shoaf, John Ouyang, Olga Sergeyeva, Alvin Estilo, Hui Li

Clin J Am Soc Nephrol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
Franz Schaefer, Djalila Mekahli, Francesco Emma, Rodney D Gilbert, Detlef Bockenhauer, Susan E Shoaf

Eur J Pediatr· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease.
Shankar Lanke, Susan E Shoaf

J Clin Pharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults.
Susan E Shoaf, Patricia Bricmont, Ann Dandurand

Eur J Clin Pharmacol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4.
Olivier Devuyst, Arlene B Chapman, Susan E Shoaf, Frank S Czerwiec, Jaime D Blais

Kidney Int Rep· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial.
Susan E Shoaf, Arlene B Chapman, Vicente E Torres, John Ouyang, Frank S Czerwiec

J Clin Pharmacol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.
Jeffrey L Woodhead, William J Brock, Sharin E Roth, Susan E Shoaf, Kim L R Brouwer

Toxicol Sci· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects.
Suresh Mallikaarjun, Charles Wells, Carolyn Petersen, Anne Paccaly, Susan E Shoaf

Antimicrob Agents Chemother· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function.
Susan E Shoaf, Patricia Bricmont, Suresh Mallikaarjun

Kidney Int· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population-based meta-analysis of furosemide pharmacokinetics.
Scott A Van Wart, Susan E Shoaf, Suresh Mallikaarjun, Donald E Mager

Biopharm Drug Dispos· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.
Wendy E Boertien, Esther Meijer, Paul E de Jong, Stephan J L Bakker, Frank S Czerwiec, Susan E Shoaf

Kidney Int· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population-based meta-analysis of hydrochlorothiazide pharmacokinetics.
Scott A Van Wart, Susan E Shoaf, Suresh Mallikaarjun, Donald E Mager

Biopharm Drug Dispos· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis.
Scott A Van Wart, Susan E Shoaf, Suresh Mallikaarjun, Donald E Mager

Biopharm Drug Dispos· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects.
Susan E Shoaf, Seong Ryul Kim, Patricia Bricmont, Suresh Mallikaarjun

Eur J Clin Pharmacol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan and Warfarin in Healthy Subjects.
Susan E Shoaf, Suresh Mallikaarjun

Clin Pharmacol Drug Dev· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis